178 related articles for article (PubMed ID: 20421219)
1. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state.
Ingram G; Hakobyan S; Hirst CL; Harris CL; Pickersgill TP; Cossburn MD; Loveless S; Robertson NP; Morgan BP
Brain; 2010 Jun; 133(Pt 6):1602-11. PubMed ID: 20421219
[TBL] [Abstract][Full Text] [Related]
2. Progranulin genetic polymorphisms influence progression of disability and relapse recovery in multiple sclerosis.
Vercellino M; Fenoglio C; Galimberti D; Mattioda A; Chiavazza C; Binello E; Pinessi L; Giobbe D; Scarpini E; Cavalla P
Mult Scler; 2016 Jul; 22(8):1007-12. PubMed ID: 26447062
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis.
Wilczak N; Ramsaransing GS; Mostert J; Chesik D; De Keyser J
Mult Scler; 2005 Feb; 11(1):13-5. PubMed ID: 15732261
[TBL] [Abstract][Full Text] [Related]
4. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis.
Fenoglio C; Ridolfi E; Cantoni C; De Riz M; Bonsi R; Serpente M; Villa C; Pietroboni AM; Naismith RT; Alvarez E; Parks BJ; Bresolin N; Cross AH; Piccio LM; Galimberti D; Scarpini E
Mult Scler; 2013 Dec; 19(14):1938-42. PubMed ID: 24277735
[TBL] [Abstract][Full Text] [Related]
5. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
Dickens AM; Larkin JR; Griffin JL; Cavey A; Matthews L; Turner MR; Wilcock GK; Davis BG; Claridge TD; Palace J; Anthony DC; Sibson NR
Neurology; 2014 Oct; 83(17):1492-9. PubMed ID: 25253748
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies as diagnostic biomarkers for the detection and subtyping of multiple sclerosis.
DeMarshall C; Goldwaser EL; Sarkar A; Godsey GA; Acharya NK; Thayasivam U; Belinka BA; Nagele RG
J Neuroimmunol; 2017 Aug; 309():51-57. PubMed ID: 28601288
[TBL] [Abstract][Full Text] [Related]
7. Neurolymphatic biomarkers of brain endothelial inflammatory activation: Implications for multiple sclerosis diagnosis.
Yun JW; Cvek U; Kilgore PCSR; Tsunoda I; Omura S; Sato F; Zivadinov R; Ramanathan M; Minagar A; Alexander JS
Life Sci; 2019 Jul; 229():116-123. PubMed ID: 31082401
[TBL] [Abstract][Full Text] [Related]
8. Analysis of potential microRNA biomarkers for multiple sclerosis.
Al-Temaimi R; Alshammari N; Alroughani R
Exp Mol Pathol; 2024 Jun; 137():104903. PubMed ID: 38772208
[TBL] [Abstract][Full Text] [Related]
9. Lower Serum Zinc Levels in Patients with Multiple Sclerosis Compared to Healthy Controls.
Pawlitzki M; Uebelhör J; Sweeney-Reed CM; Stephanik H; Hoffmann J; Lux A; Reinhold D
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30049983
[TBL] [Abstract][Full Text] [Related]
10. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
11. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
12. LncRNAs, MALAT1 and lnc-DC as potential biomarkers for multiple sclerosis diagnosis.
Shaker OG; Mahmoud RH; Abdelaleem OO; Ibrahem EG; Mohamed AA; Zaki OM; Abdelghaffar NK; Ahmed TI; Hemeda NF; Ahmed NA; Mansour DF
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30514825
[TBL] [Abstract][Full Text] [Related]
13. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
15. Serum and cerebrospinal fluid nitrite and nitrate levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Yuceyar N; Taşkiran D; Sağduyu A
Clin Neurol Neurosurg; 2001 Dec; 103(4):206-11. PubMed ID: 11714562
[TBL] [Abstract][Full Text] [Related]
16. Involvement of cytotoxic Eomes-expressing CD4
Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
[TBL] [Abstract][Full Text] [Related]
18. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
19. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
20. Serum homocysteine levels in relation to clinical progression in multiple sclerosis.
Teunissen CE; Killestein J; Kragt JJ; Polman CH; Dijkstra CD; Blom HJ
J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1349-53. PubMed ID: 18676406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
